Dual Antiglutamate Therapy in Super-Refractory Status Epilepticus After Cardiac Arrest (SUPER-CAT Study).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Beretta Simone, Pozzi Matteo, Tagliabue Simone, Bianchi Elisa, Rossi Emanuela, Pasini Francesco, Giglio Angela, Cereda Giulia Sofia, Morotti Colleoni Carlo, Pederzoli Giulia, Giovannini Giada, Orlandi Niccolò, Meletti Stefano, Gaiani Alessandra, Filipponi Stefania, Cucino Alberto, Normanno Marco, Mariani Ilaria, Scanziani Margherita, Giani Marco, Diamanti Susanna, Coppo Anna, DiFrancesco Jacopo C, Stabile Andrea, Tinti Lorenzo, Florio Igor, Sist Chiara, Corona Marta, Pinna Beatrice, Orlandini Francesco, Cossu Giovanni, Ferlisi Monica, Casartelli-Liviero Marilena, Misirocchi Francesco, Florindo Irene, Zinno Lucia, Bartolini Yerma, Longoni Marco, Russo Emilio, Grippo Antonello, Ferrarese Carlo, Foti Giuseppe, Avalli Leonello
Аннотация
METHODS: Multicenter cohort study including patients with postanoxic SRSE meeting the following criteria: bilaterally preserved N20 cortical responses, intact pupillary reflexes, and absence of generalized periodic discharges. Patients treated with dual antiglutamate therapy (DUAL; ketamine 1.5-7.5 mg/kg/h for 3 days plus perampanel 6-12 mg/d for 5 days with tapering) were compared with patients receiving other combinations of antiseizure and anesthetic agents (OTHERS). The primary outcome was resolution of SE. Secondary outcomes included awakening to follow commands and good neurologic outcome at 6 months (modified Rankin Scale 0-3) in patients with fewer than 2 unfavorable multimodal prognostic indicators and 6-month mortality for the entire cohort. Safety analysis included in-hospital mortality and potentially treatment-related adverse events. Patients treated with single antiglutamate agents were described separately.
RESULTS: Between May 2012 and May 2025, 95 of 1,352 consecutive post-cardiac arrest intensive care unit patients met inclusion criteria (mean age 66, interquartile range 55-73; 41% female; DUAL = 43; OTHERS = 41; single antiglutamate = 11). Compared with OTHERS, DUAL was associated with a higher rate of SE resolution (84% vs 49%; OR 5.4; 95% CI 1.9-14.9; p = 0.001), a greater likelihood of awakening before discharge (56% vs 32%; OR 2.7; 95% CI 1.0-7.3; p = 0.053) and lower 6-month mortality (52% vs 74%; OR 0.37; 95% CI 0.15-0.97; p = 0.043). A trend toward better 6-month neurologic outcome was observed in the DUAL group (39% vs 25%; OR 1.89; 95% CI 0.64-5.56; p = 0.245). Reversible cholestatic liver injury occurred more frequently in DUAL group, compared with OTHERS (77% vs 27%; OR 9.00; 95% CI 3.34-24.19; p < 0.001).
DISCUSSION: In patients with postanoxic SRSE without unfavorable prognostic indicators, dual antiglutamate therapy was highly effective in resolving SE and was associated with improved short-term clinical outcomes.
TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT05756621.